How does pretransplant 𝘐𝘋𝘏1 and 𝘐𝘋𝘏2 MRD affect posttransplant outcomes in patients with AML? 

The AML Hub spoke to Gege Gui, National Institutes of Health, Maryland, US. We asked, How does pretransplant IDH1 and IDH2 measurable residual disease (MRD) affect posttransplant outcomes in patients with acute myeloid leukemia (AML)?
Gui provides an overview of the Pre-MEASURE study, a retrospective study assessing the impact of MRD, detected by next-generation sequencing, on posttransplant outcomes in patients with AML who are in first complete remission prior to allogeneic hematopoietic stem cell transplantation using a variety of MRD markers. She then discusses how pretransplant IDH1 and IDH2 MRD affect outcomes, and how these mutations compare with NMP1 and FLT3-internal tandem duplication mutations as MRD markers. Finally, Gui highlights the MEASURE study, which aims to validate these findings prospectively and optimize prognostication using MRD for patients with AML.